La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
China Resources Pharmaceutical Group Dividendo
Dividendo criteri di controllo 2/6
China Resources Pharmaceutical Group è una società che paga dividendi con un rendimento attuale pari a 2.98%, ben coperto dagli utili.
Informazioni chiave
3.0%
Rendimento del dividendo
25%
Rapporto di remunerazione
| Rendimento medio del settore | 3.5% |
| Prossima data di pagamento dei dividendi | n/a |
| Data di stacco del dividendo | n/a |
| Dividendo per azione | HK$0.166 |
| Utile per azione | HK$0.61 |
| Previsione del rendimento del dividendo a 3 anni | 3.7% |
Aggiornamenti recenti sui dividendi
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28Recent updates
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued
Feb 14If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%
Jan 17
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Nov 29Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Sebbene i pagamenti dei dividendi siano rimasti stabili, 3320 paga dividendi da meno di 10 anni.
Dividendo in crescita: I pagamenti dei dividendi di 3320 sono aumentati, ma la società ha pagato dividendi solo per 7 anni.
Rendimento dei dividendi rispetto al mercato
| China Resources Pharmaceutical Group Rendimento dei dividendi rispetto al mercato |
|---|
| Segmento | Rendimento dei dividendi |
|---|---|
| Azienda (3320) | 3.0% |
| Fondo del 25% del mercato (HK) | 3.5% |
| Top 25% del mercato (HK) | 8.3% |
| Media del settore (Pharmaceuticals) | 3.5% |
| Previsione dell'analista in 3 anni (3320) | 3.7% |
Dividendo notevole: Il dividendo di 3320 ( 2.98% ) non è degno di nota rispetto al 25% inferiore dei pagatori di dividendi nel mercato Hong Kong ( 3.52% ).
Dividendo elevato: Il dividendo di 3320 ( 2.98% ) è basso rispetto al 25% dei maggiori pagatori di dividendi nel mercato Hong Kong ( 8.22%.
Distribuzione degli utili agli azionisti
Copertura degli utili: Grazie al suo payout ratio ( 25.1% ) ragionevolmente basso, i pagamenti dei dividendi di 3320 sono ben coperti dagli utili.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Grazie al suo basso cash payout ratio ( 7.7% ), i pagamenti dei dividendi di 3320 sono completamente coperti dai flussi di cassa.